An international team of researchers has reported findings indicating that a new monoclonal antibody could be effective at preventing frequent migraine attacks. In addition, they concluded that the antibody could reduce the quantity of medication patients take for migraine headaches. The team, based in Denmark, Germany and the USA, presented their results at the 3rd European Academy of Neurology Congress in Amsterdam (the Netherlands).
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.